ASLAN Pharmaceuticals Limited ASLN
Set alert
0.60 0.00 0.00%
At close · Jul 18
0.60 Day range 0.6999
52-week range unavailable
- Open
- 0.63
- Prev close
- 0.60
- Mkt cap
- 1.70M
- Vol
- 769.82K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.60
- High
- 0.6999
- Forward P/E
- -0.03
- Beta
- 1.40
- Short ratio
- 1.85
- Inst. own
- 13.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 1.07
- 200-d avg
- 3.48
- 1y target
- 72.00
2Y chart
Events in this range
- Mar 13, 2023Split: 1 for 5
- Apr 28, 2023Earnings: —; estimate -6.4; surprise —%
- May 30, 2023Rating: Roth MKM · — → Buy
- Jun 22, 2023Rating: HC Wainwright & Co. · Buy → Buy
- Jul 6, 2023Rating: HC Wainwright & Co. · Buy → Buy
- Aug 11, 2023Earnings: —; estimate -6.96; surprise —%
- Oct 27, 2023Earnings: —; estimate -6.8; surprise —%
- Apr 12, 2024Earnings: —; estimate 0; surprise —%
- May 9, 2024Earnings: —; estimate -5.44; surprise —%
- Jul 3, 2024Split: 1 for 8
- Aug 9, 2024Earnings: —; estimate 0; surprise —%
Signals (87)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Jul 31, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 15, 2024 | 2 years ago |
| RSI: Oversold | Jul 15, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 10, 2024 | 2 years ago |
| RSI: Oversold | Jul 5, 2024 | 2 years ago |
| RSI: Oversold | Jul 2, 2024 | 2 years ago |
| RSI: Oversold | Jun 24, 2024 | 2 years ago |
| RSI: Oversold | Jun 18, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 11, 2024 | 2 years ago |
| MACD: Buy Signal | May 9, 2024 | 2 years ago |
| MACD: Sell Signal | May 8, 2024 | 2 years ago |
| MACD: Buy Signal | May 1, 2024 | 2 years ago |
| SMA: Bearish | Mar 28, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 19, 2024 | 2 years ago |
| RSI: Overbought | Mar 11, 2024 | 2 years ago |
| RSI: Overbought | Feb 29, 2024 | 2 years ago |
| SMA: Bullish | Feb 28, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 28, 2024 | 2 years ago |
| SMA: Bearish | Feb 16, 2024 | 2 years ago |
| SMA: Bullish | Feb 13, 2024 | 2 years ago |
| SMA: Bearish | Feb 8, 2024 | 2 years ago |
| SMA: Bullish | Feb 6, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 6, 2024 | 2 years ago |
| SMA: Bearish | Feb 2, 2024 | 2 years ago |
| SMA: Bullish | Jan 29, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 26, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 24, 2024 | 2 years ago |
| SMA: Bearish | Jan 16, 2024 | 2 years ago |
| RSI: Overbought | Jan 12, 2024 | 2 years ago |
| SMA: Bullish | Jan 10, 2024 | 2 years ago |
| RSI: Oversold | Dec 18, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 14, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 24, 2023 | 2 years ago |
| RSI: Oversold | Nov 22, 2023 | 2 years ago |
| RSI: Oversold | Nov 1, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 30, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 27, 2023 | 3 years ago |
| RSI: Oversold | Oct 27, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 26, 2023 | 3 years ago |
| RSI: Oversold | Oct 19, 2023 | 3 years ago |
| RSI: Oversold | Oct 13, 2023 | 3 years ago |
| RSI: Oversold | Oct 3, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 29, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 28, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 27, 2023 | 3 years ago |
| RSI: Oversold | Aug 25, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 9, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 25, 2023 | 3 years ago |
| RSI: Oversold | Jul 25, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 21, 2023 | 3 years ago |
| RSI: Oversold | Jul 7, 2023 | 3 years ago |
| SMA: Bearish | Jul 6, 2023 | 3 years ago |
| SMA: Bearish | Jun 21, 2023 | 3 years ago |
| SMA: Bullish | Jun 20, 2023 | 3 years ago |
| SMA: Bearish | Jun 16, 2023 | 3 years ago |
| SMA: Bullish | Jun 15, 2023 | 3 years ago |
| SMA: Bearish | Jun 14, 2023 | 3 years ago |
| SMA: Bullish | Jun 13, 2023 | 3 years ago |
| SMA: Bearish | Jun 9, 2023 | 3 years ago |
| MACD: Sell Signal | May 15, 2023 | 3 years ago |
| RSI: Overbought | May 8, 2023 | 3 years ago |
| RSI: Overbought | Apr 24, 2023 | 3 years ago |
| RSI: Overbought | Apr 20, 2023 | 3 years ago |
| SMA: Bullish | Apr 14, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 3, 2023 | 3 years ago |
| SMA: Bearish | Mar 9, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 14, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 7, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 31, 2023 | 3 years ago |
| RSI: Overbought | Jan 24, 2023 | 3 years ago |
| RSI: Overbought | Jan 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 4, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 4, 2023 | 3 years ago |
| RSI: Oversold | Dec 30, 2022 | 3 years ago |
| SMA: Bearish | Dec 15, 2022 | 3 years ago |
| SMA: Bullish | Dec 13, 2022 | 3 years ago |
| SMA: Bearish | Dec 7, 2022 | 3 years ago |
| MACD: Sell Signal | Dec 7, 2022 | 3 years ago |
| SMA: Bullish | Nov 22, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 4, 2022 | 3 years ago |
| MACD: Sell Signal | Oct 27, 2022 | 4 years ago |
| RSI: Oversold | Oct 26, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 18, 2022 | 4 years ago |
| RSI: Oversold | Oct 7, 2022 | 4 years ago |
| RSI: Oversold | Oct 3, 2022 | 4 years ago |
| RSI: Oversold | Sep 29, 2022 | 4 years ago |
| RSI: Oversold | Sep 23, 2022 | 4 years ago |
Key statistics
- Market cap
- 1.70M
- Enterprise value
- 288.33M
- Trailing P/E
- 0.00
- Forward P/E
- -0.03
- PEG ratio
- 0.00
- Price / sales
- 0.14
- Price / book
- 0.00
- EPS (TTM)
- -16.00
- Beta
- 1.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -291.89%
- Revenue (TTM)
- 12.00M
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 18.40M
- Total debt
- 26.67M
- Return on equity
- 0.00%
- Shares outstanding
- 2.83M
- Short % of float
- 1.46%
- 50-day average
- 1.07
- 200-day average
- 3.48
Analyst view
Consensus: buy
Buy
Price target (mean) 72.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -3.60.
Financials — quick view
ASLN Revenue — quarterly 0
ASLN Net income — quarterly -9.92M
ASLN EPS — quarterly -4.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -5.44 | — | — | — |
| Apr 12, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Oct 27, 2023 | Sep 1, 2023 | -6.80 | — | — | — |
| Aug 11, 2023 | Jun 1, 2023 | -6.96 | — | — | — |
| Apr 28, 2023 | Mar 1, 2023 | -6.40 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2023 | Roth MKM | reit | Buy | Buy |
| Jul 6, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 25, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 22, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 30, 2023 | Roth MKM | init | — | Buy |
About ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Singapore
- Website
- aslanpharma.com
News
- Critical Contrast: ASLAN Pharmaceuticals (NASDAQ:ASLN) vs. Argos Therapeutics (OTCMKTS:ARGSQ)
- Analyzing ASLAN Pharmaceuticals (NASDAQ:ASLN) & CannTrust (OTCMKTS:CNTTF)
- Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates
- ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
- Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
- All You Need to Know About ASLAN Pharmaceuticals (ASLN) Rating Upgrade to Buy
- Here's Why ASLAN Pharmaceuticals (ASLN) Could be Great Choice for a Bottom Fisher
- ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
Your note
Sign in to keep a note on ASLN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vivo Capital, LLC | 37.39% | 2,840,908 | 10.37M | Jun 29, 2023 |
| Tang Capital Management, LLC | 14.85% | 1,128,068 | 4.12M | Jun 29, 2023 |
| BVF Inc. | 13.82% | 1,049,999 | 3.83M | Jun 29, 2023 |
| Parkman Healthcare Partners LLC | 6.67% | 506,621 | 1.85M | Jun 29, 2023 |
| Temasek Holdings (Private) Limited | 4.42% | 335,615 | 1.22M | Jun 29, 2023 |
| Sio Capital Management, LLC | 3.34% | 254,150 | 927.65K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR Portfolio Emerging Markets ETF | 0.13% | 9,908 | 21.05K | Aug 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.10% | 7,968 | 31.87K | May 30, 2023 |